Obesity drugs widen logistics and formats

Novo Nordisk just pushed the obesity-drug fight onto three fronts at once: a pill, a shipping change, and a stronger combo shot still in testing. In the span of weeks, it added a new way to take Wegovy, made the injectable easier to move through hot supply chains in Europe, and posted fresh late-stage data for CagriSema. (fda.gov) (novonordisk.com) (adameetingnews.org) The first move was the United States approval of Wegovy tablets, a once-daily oral version of semaglutide for adults with obesity, or overweight with a weight-related condition. The Food and Drug Administration label lists a 25 milligram tablet taken once each day, alongside the existing injectable form. (fda.gov) Semaglutide is the ingredient doing the work in both Wegovy and Ozempic, and it acts on appetite and blood sugar signals. The tablet matters because a daily pill fits patients who do not want weekly injections, even if they are taking the same core drug. (fda.gov) (cbsnews.com) The pill did not arrive with the same weight-loss numbers as the most powerful injectable regimens. In the Phase 3 OASIS 4 trial cited in coverage of the approval, people on oral Wegovy lost 13.6% of body weight on average over about 64 weeks, versus 2.2% on placebo. (appliedclinicaltrialsonline.com) (cbsnews.com) The second move was not about biology at all. It was about temperature, which has been one of the quiet bottlenecks in getting obesity drugs from factory to pharmacy. (novonordisk.com) (ema.europa.eu) On April 9, 2026, Novo Nordisk said Wegovy injection became the first glucagon-like peptide-1 weight-loss treatment approved in the European Union for 48-hour controlled-temperature delivery. The company said the new rule allows shipping at up to 30 degrees Celsius, or 86 degrees Fahrenheit, for 48 hours. (novonordisk.com) (ec.europa.eu) That sounds minor until you picture pallets sitting on airport tarmacs, trucks crossing southern Europe in summer, or boxes moving through regional depots without perfect refrigeration. A 48-hour window at 30 degrees Celsius gives distributors more room to reroute delays without automatically spoiling product. (novonordisk.com) (ec.europa.eu) The third move is CagriSema, which is still experimental and combines semaglutide with cagrilintide, an amylin analogue that targets fullness through a second pathway. In REDEFINE 1, Novo said average weight loss at 68 weeks reached 22.7% under the trial’s treatment-adherence analysis and 20.4% regardless of adherence, versus 2.3% and 3.0% for placebo. (adameetingnews.org) (clinicaltrials.gov) (kommunikasjon.ntb.no) Novo also said 50.7% of participants with obesity who took CagriSema finished the trial below the body mass index threshold of 30, down from a mean starting body mass index of 38. That is the kind of result drugmakers use to argue that the next round of obesity treatments will not just be easier to take, but also harder to beat. (kommunikasjon.ntb.no) Put together, these are three different answers to three different problems. One patient wants a pill instead of a needle, one wholesaler needs more heat tolerance in transit, and one company wants a stronger next-generation shot before rivals catch up. (fda.gov) (novonordisk.com) (adameetingnews.org) That is why this week’s news was bigger than a single approval. The obesity market is no longer just a race over who has the best molecule; it is becoming a race over format, temperature tolerance, and how many patients a drug can realistically reach once it leaves the factory. (fda.gov) (ec.europa.eu) (clinicaltrials.gov)